Needham & Company
View Older Stories
-
Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Dermira (DERM) Prices 9.81M Shares Common Offering at $13.25/Sh
-
Dermira Prices $130.0 Million Public Offering of Common Stock
-
Dermira (DERM) Plans Public Offering of Common Stock
-
Dermira Announces Proposed Public Offering of Common Stock
-
Dermira to Present at 17th Annual Needham Healthcare Conference
-
Dermira (DERM) PT Lowered to $19 at Needham & Company; 'Focus Shifts to Underappreciated Assets'
-
Dermira (DERM): Cimzia Collaboration Loss Removes $3 Of Value - Needham
-
Dermira (DERM): KOL Call Reinforces Opportunity In hyperhidrosis - Needham
-
Dermira Announces Closing of 3.00% Convertible Senior Notes Offering
-
Dermira to Present at Needham 16th Annual Healthcare Conference
-
Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
UPDATE: Dermira (DERM) Prices 5M Shares at $33.70
-
Dermira Prices $168.5 Million Public Offering of Common Stock
-
Dermira (DERM) Plans 3.7M Share Offering of Common Stock
-
Dermira Announces Proposed Public Offering of Common Stock
-
Needham & Company Remains Positive on Dermira (DERM) Following Strong CIMPASI-2 Trial Data
-
Needham & Company Reiterates Buy on Dermira (DERM) Following Licensing Agreement
-
Dermira (DERM): Investment Thesis Playing Out, Reiterate Outperform - Needham
-
Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Dermira (DERM) Prices 4.5M Shares Offering at $28
-
Dermira Prices $126 Million Public Offering of Common Stock
-
Dermira (DERM) Plans Stock Offering
-
Dermira Announces Proposed Public Offering of Common Stock
-
Dermira (DERM) Positive Ph 3 Results for DRM04, PT to $46 - Needham & Company
-
Dermira (DERM) PT Lifted to $42 at Needham & Company Amid Acne Results
-
Dermira to Present at 15th Annual Needham Healthcare Conference
-
Needham & Company Reiterates Buy Rating on Dermira (DERM) Ahead of DRM01 and DRM04 Data
-
Dermira (DERM) Completed Phase III Enrollment Ahead of Schedule - Needham & Company Raises PT to $38
-
Notable Analyst Rating Changes 12/18: (CRM) (COLM) (DERM) Upgraded; (FOSL) (LHO) (SDLP) Downgraded
-
Notable Analyst Rating Changes 8/19: (SJM) (WTW) (GOOG) Upgraded; (ESPR) (AFL) (MEOH) Downgraded
-
Needham & Company Raises Price Target on Dermira (DERM) as Assets Enter Late-Stage Clinical Trials
-
Dermira Announces Closing of Follow-on Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Dermira (DERM) Prices 4.5M Common Stock Follow-on at $21.50/Share
-
Dermira Prices Follow-On Public Offering of Common Stock
-
Dermira Commences Follow-on Public Offering of Common Stock
-
Dermira to Present at the 14th Annual Needham Healthcare Conference
-
Needham & Company Starts Dermira (DERM) at Buy
-
Dermira (DERM) IPO Opens Higher

